China Biologic Products is known as one of the leading plasma-based pharmaceutical companies in the People’s Republic of China. The young company took a major step towards catching the attention of investors on Wall Street with the announcement that on September 11, 2009 they entered into a strategic research and development agreement with the Institute of Blood Transfusion (IBT) to strengthen their research and development capabilities and manufacturing processes.

IBT, which is a division of the Chinese Academy of Medical Sciences and Peking Union Medical College, is a leading institute in China which specializes in a variety of plasma-based research that includes the safety of blood transfusions and molecular biology. The union between China Biologic and IBT will include the use of IBT’s technology to enhance safe and efficient plasma collection, and increase the range of plasma-derivative products that can be manufactured by the company. Another key aspect

DrStockPick.com Stock Report!

Thursday September 10, 2009

**************************************************************

Concurrent (Nasdaq: CCUR), a worldwide leader in video and media data and advertising solutions, is announcing the international extension of its three-screen strategy to bring open, commercial and intelligent video solutions to television, personal computers and mobile devices. First announced in the U.S. in March 2009, Concurrent’s strategy now leverages the company’s technological expertise to enable its customers to deliver, monetize and drive the future of video around the globe.

Diguang International Development Co., Ltd. (OTC Bulletin Board: DGNG) today announced that Shenzhen Diguang Electronics Co., Ltd. (”Diguang”) was selected as a member of the Standard

China Biologic Products, Inc. has been gaining a reputation as one of the leading plasma-based pharmaceutical companies in the People’s Republic of China and has obtained great success operating through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co. and Chongging Dalin Biologic Technologies Co. While the young company has been making strides across the globe, they obtained a major asset to their company with the announcement that they have appointed Dr. Vincent Yi-Wu Xie to become the new Director of Research and Development.

Dr. Xie brings a lot of experience and credibility to the China Biologic team. Dr. Xie is a veteran in the biopharmaceutical industry and has published several papers and articles related to the field of plasma-based research. He holds a number of patents related to his biopharmaceutical research, including research on plasma-derived hyperimmune globulins and alpha-1 proteinase inhibitor, and has received the Guangzhou City Science